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ABSTRAK
Tujuan: untuk mengetahui apakah ST2 dapat berperan sebagai petanda perbaikan klinis pada pasien gagal 
jantung NYHA III dan IV. Metode: penelitian ini merupakan penelitian longitudinal, pre dan post-test tanpa 
kontrol. Subyek penelitian adalah 23 orang pasien gagal jantung klasifikasi NYHA III dan IV. Pemeriksaan 
ST2 dilakukan pada awal perawatan dan hari terakhir perawatan pasien di rumah sakit. Hasil: dari 23 orang 
pasien gagal jantung didapatkan klasifikasi NYHA III sebesar 70% dan IV sebesar 30%. Pasien laki-laki lebih 
banyak daripada perempuan (51.4% vs 48.6%). Median usia NYHA III 52 tahun dan rerata usia NYHA IV 58 
tahun. Penyebab gagal jantung terbanyak adalah CAD 52% dan non CAD 48%. Kadar ST2 tidak berkorelasi 
dengan usia, lama perawatan, jenis kelamin dan faktor penyebab gagal jantung. Kadar ST2 pada NYHA IV 
58,82±37,36 ng/ml cenderung lebih tinggi dibandingkan NYHA III 30,75 (14,4–84,5), tetapi perbedaan ini tidak 
bermakna (p=0.89). Kadar ST2 pada awal hari perawatan lebih tinggi bermakna dibandingkan pada akhir hari 
perawatan 31,4 (14-129,2) ng/mL vs 18,4 (7,6-77,8) ng/mL, dengan p=0,001. Hasil ini menunjukkan dengan 
adanya perbaikan klinis penderita, terjadi penurunan kadar ST2 yang bermakna. Kesimpulan: ST2 dapat 
digunakan sebagai petanda untuk menentukan perbaikan klinis gagal jantung NYHA III dan IV.
Kata kunci: ST2, Gagal jantung, NYHA III and IV.
ABSTRACT
Aim: to find whether ST2 can be used to determine clinical improvement in patients with NYHA III and IV 
heart failure. Methods: this is a longitudinal, pre and post-test study without a control group. Study subjects 
are 23 NYHA III and IV heart failure patients. ST2 was tested at the start and end of hospital treatment. 
Results: of 23 heart failure patients, 70% were classified as NYHA III while 30% were NYHA IV. There were 
more male subjects than females (51.4% vs. 48.6%). Median age for NYHA III heart failure patients was 52 years 
and mean age for NYHA IV heart failure patients was 58 years. Heart failure was mostly caused by coronary 
artery disease (52%). ST2 levels did not correlate with age, length of care, sex and cause of heart failure. ST2 
levels in NYHA IV heart failure patients (58.82±37.36 ng/mL) tended to be higher than the one in NYHA III 
group (30.75 [14.4-84.5] ng/mL), but the difference was statistically not insignificant (p=0.89). ST2 levels at 
the start of treatment was significantly higher than at the end (31.4 [14-129.2] ng/mL vs. 18.4 [7.6-77.8] ng/
mL), p=0.001. This shows that clinical improvement is associated with significant reduction of ST2 levels. 
Conclusion: ST2 can be used as a marker to determine clinical improvement in NYHA III and IV heart failure.
Key words: ST2, heart failure, NYHA III and IV.
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INTRODUCTION
Heart failure has become a growing 
problem in the world, causing a great number 
of cardiovascular morbidity and mortality. 
The disease is also a major source of expense 
due to its high rate of hospital stay.1,2 Several 
studies reported that the incidence of heart 
failure increases with age. In Northern America 
(United States and Canada) and Europe, the 
risk for a person to have heart failure is 1 in 5 
with a mean age of more than 40 years.3,4 Life 
expectancy for heart failure patients is increasing 
because of improvements in health facilities and 
treatment.4 Those patients commonly have left 
ventricular dysfunction and will progress to a 
state of chronic heart failure, thus prompting 
them for in-hospitalization.5-10
The New York Heart Association (NYHA) 
classification is the most common classification 
to determine heart failure progressivity based 
on symptoms of functional limitation. Heart 
failure is classified into four functional classes. 
NYHA class I is asymptomatic, class II has mild 
symptoms, class III has moderate symptoms 
(dyspnea, fatigue, palpitation, or chest pain 
during light activities), and class IV has severe 
symptoms (dyspnea, fatigue, palpitation, or 
chest pain at rest).3,11 The NYHA classification is 
subjective so there is a need among clinicians for 
a more objective laboratory test to differentiate 
heart failure based on severity.
B-type natriuretic peptide (BNP) is a member 
of the natriuretic peptides, of which secretion 
is stimulated by ventricular wall stretch and 
its plasma levels correlates with the severity of 
heart failure. Precursor of BNP is synthesized 
in ventricular myocytes and broken down by 
a protease to its active form (BNP) and amino 
terminal pro B-type natriuretic peptide (NT-
proBNP).12-14 NT-proBNP levels in the blood 
equals BNP, but it has a longer half-life (60-120 
minutes) than BNP (15-20 minutes).13-15 Patient 
characteristics influence NT-proBNP levels, 
which is higher in females and increases with age. 
NT-proBNP is also affected by kidney function 
because its clearance through kidneys.16-19
A new marker for heart failure that is 
currently gaining popularity is ST2. ST2 (growth 
Stimulation expressed gene 2) is a protein that 
belongs in the interleukin-1 (IL-1 receptor) family 
and has two isoforms, transmembrane receptor 
form (ST2L) and soluble ST2 (ST2). In heart 
failure, ST2 will rise because of cardiomyocyte 
stretch.20 Earlier reports state that high ST2 
levels signifies an ongoing process of damage 
or remodeling in the heart. Heart remodeling 
cannot be monitored based on symptoms because 
it produces none. It also cannot be detected in 
physical examination. Radiographic examination 
has some value in detecting heart remodeling, 
but only if the damage is severe. In heart failure 
patients, ST2 levels strongly correlates with the 
worsening of disease and mortality.21 ST2 levels 
increases along with heart hypertrophy, fibrosis, 
and ventricle dysfunction. Expression of ST2 
starts around one hour after myocyte stretch in 
a patient with myocardial infarct.22 Rehman et 
al.23 in 2008 reported that patients with worse 
clinical symptoms in NYHA class IV group has 
higher ST2 levels than the ones in NYHA class 
III group. The advantage of ST2 over BNP/NT-
proBNP is that it is not affected by conditions like 
sex, left ventricle hypertrophy, tachycardia, right 
ventricle overload, and factors external to the 
heart, such as hypoxemia, kidney dysfunction, 
metabolic risk factors, hepatic cirrhosis with 
ascites, and sepsis.24
Muller showed that ST2 is superior than 
NT-proBNP as a prognostic marker.25 Bhardwaj 
et al26 stated that not only did ST2 show heart 
muscle damage, but it also changed in response 
to the given treatment. As the heart improves, 
ST2 levels will drop. Hence, ST2 can be 
used for prognosis and treatment monitoring. 
Based on the results of those studies, we will 
conduct a research to discover the role of ST2 
in determining clinical improvement in NYHA 
III and IV heart failure patients after treatment.
METHODS
This is a longitudinal, pre and post-test study 
without a control group. Study subjects were 
patients newly diagnosed with NYHA III and IV 
heart failure in Cipto Mangunkusumo hospital. 
Diagnosis of heart failure was established by 
cardiologist as noted in medical records. ST2 
test was conducted upon entry to the hospital 
(before treatment) and upon discharge (after 
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treatment). Patients are discharged when clinical 
improvements are found. Clinical improvements 
include functional improvement of NYHA or 
fluid overload or electrolyte imbalance, are under 
control. Study subjects were NYHA III and IV 
heart failure patients that fulfilled the inclusion 
criteria.
The inclusion criteria are patients newly 
diagnosed with NYHA III and IV heart failure, 
18-75 years of age, and willing to participate in 
the study by signing a written informed consent. 
Subject was considered a drop out if the patient 
withdrawed, discharged him/herself against 
medical advice, or died. Sample size required 
to determine whether there was a significant 
difference between ST2 levels in the beginning 
and the end of hospital stay is 23. Sample size 
was calculated using the appropriate sample size 
formula with combined standard deviation of 0.6 
ng/mL, d of 0.31, significance (2α) of 1.64 and 
power (β) of 0.89.25
Six mL of vein blood was collected from 
the cubital vein in a tube without anticoagulant. 
Serum was separated under one hour after 
blood collection by centrifuging the sample at 
3000 G for 10 minutes. Serum was then stored 
in Eppendorf tubes at -200C. By the time a test 
is about to be performed, serum is thawed by 
removing it from the freezer and putting it in 
room temperature (20-250C). ST2 levels test was 
carried out using sandwich double monoclonal 
antibody ELISA and Presage®ST2 Assay 
reagent.26
Before the ST2 test was performed, the 
instrument was calibrated. Afterward, within-run 
precision and accuracy analysis were carried out 
by measuring test control five consecutive times 
in the same day as sample testing.
Statistical Analysis
ST2 results were recorded and calculated 
for mean and standard deviation if they were 
normally distributed, or for median and range 
(minimum, maximum) if they were not.
All collected data were analyzed, with 
the exception of patients who died or were 
discharged from the hospital before observation 
was done. They were recorded as, respectively, 
lost cases or lost to follow up.
The study event was clinical improvement 
when a patient was discharged. Survival analysis 
was performed to evaluate ST2 as prognostic 
indicator of patients. ST2 levels at the start and 
end of treatment were analyzed using paired 
t-test for parametric data, and Wilcoxon signed 
rank for non-parametric data. ST2 levels in 
groups NYHA III and IV were analyzed using 
independent t-test for parametric data, and 
Mann-Whitney for non-parametric data. Logistic 
regression analysis was also performed to learn 
the effect of age, sex, causes of heart failure, and 
length of hospital stay to ST2 levels difference. 
Beforehand, bivariate analysis (Chi Square or 
Fisher’s exact test) was carried out to determine 
variables that would be used in the logistic 
regression analysis. If none of the expected 
count values were <5, the variable qualified for 
chi square. If at least one of the expected count 
values was <5, Fisher’s exact test was used for 
that variable. Variables that proceeded to the 
logistic regression analysis were the ones with 
p<0.25. Strength of association between age, sex, 
causes of heart failure, length of hospital stay, 
and ST2 levels difference was described in the 
OR exponential β (EXP β).
RESULTS
Within-run precision and accuracy tests were 
performed using Presage®ST2 control kit BC 
1066 for five consecutive times before sample 
testing. The range value for normal control is 
18.8-30 ng/mL. Within-run CV was 3.63% and 
deviation was -6-2.4%.
During the study, there were 25 subjects. 
Twenty three finished the study and two dropped 
out. One died after 38 days of treatment, and one 
died at home on day 45 after discharging himself 
against medical advice. He was treated for 18 
days. The subjects were NYHA III & IV heart 
failure patients who fulfilled inclusion criteria. 
There were 16 patients in the NYHA III group 
(69.6%) and seven in NYHA IV (30.4%).
Median age of study subjects was 54 years 
with a range of 29-67 years. In NYHA III group, 
the age range was 29-62 years with a median of 
52 years, while in NYHA IV there were older 
subjects with an age range of 51-67 years and a 
median of 58 years.
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There were more males than females. 
Thirteen subjects were males (56.5%) and 10 
were females (43.5%). This was also found in 
both groups. NYHA III group had nine male 
subjects (39.1%), and NYHA IV group had four 
male subjects (17.4%) as seen in Table 1.
Figure 2 shows that ST2 levels at the start of 
treatment was significantly higher than the end.
Table 1. Subject’s characteristics




n (%) 16 (69.6) 7 (30.4) 23 (100.0)
Age (years), 
median (IQR) 52 (29-62) 58 (51-67) 54 (29-67)
Sex (males),  
n (%) 9 (39.1) 4 (17.4) 13 (56.5) 
Causing factor
 - CAD 7 (30.5) 6 (26.1) 13 (56.6)
 - Non CAD 
(HT, AF, VHD, 
DM)
4 (17.3) 6 (26.1) 10 (43.4)
CAD=coronary arterial disease, HT=hypertension, 
DM=diabetes mellitus, AF=atrial fibrillation, VHD=valvular 
heart disease
Median of ST2 levels at the start of treatment 
in NYHA III group was 30.75 (14.4-84.5 ng/
mL), while the mean in NYHA IV group was 
58.82±37.36 ng/mL. There was no significant 
difference between ST2 levels at the start of 
treatment in NYHA III and NYHA IV group 
with a p of 0.89. The boxplot in Figure 1 shows 
that ST2 levels in NYHA IV group is higher than 
the one in NYHA III group, but the difference 
is insignificant.
Table 2. Bivariate analysis of age, sex, causes of heart 





n ≤ 13 n > 13
Age, n (%)
 - ≤50 years 4 (33.3) 1 (0.1) 0.317*
 - >50 years 8 (66.7) 10 (91.0)
Sex, n (%)
 - Male 7 (58.3) 6 (54.5) 1.00*
 - Female 5 (41.7) 5 (45.4)
Causes of heart failure, n (%)
 - CAD 8 (66.7) 5 (45.4) 0.414*
 - NonCAD 4 (33.3) 6 (54.5)
Length of hospital stay, n (%)
 - ≤20 days 8 (66.7) 4 (36.4) 0.146**
 - >20 days 4 (33.3) 7 (63.6)
* = Chi Square test, ** = Fisher’s exact test
The test yielded a p value of 0.001, indicating 
a significant difference. The median of ST2 levels 
at the start of treatment was significantly different 
than at the end of treatment.
The effect of age, sex, causes of heart failure, 
and length of hospital stay to ST2 levels difference 
was analyzed with logistic regression analysis. 
Beforehand, the variables were tested against ST2 
levels difference using Fisher’s exact test or Chi 
Square. ST2 levels difference is the difference 
between ST2 levels median at the start and the 
end of treatment. Its value is classified into two, 










NYHA III NYHA IV
Figure 1. Boxplot of ST2 levels at the start of treatment in 
NYHA III and NYHA IV groups
Median of ST2 levels in groups III and IV 
at the start of treatment was 31.4 ng/mL with a 
range of 14.0-129.2 ng/mL, while median of ST2 
levels in both groups at the end of treatment was 











Figure 2. Boxplot of ST2 levels in NYHA III and IV groups 
at the start and end of treatment
Logistic regression analysis was done to 
the length of hospital stay variable (p<0.25). 
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study subjects.29 The Rotterdam study in 2004 
found a higher incidence of heart failure in 
males (17.6/1000 persons/year) than females 
(12.5/1000 persons/year).30 Mosterd reported that 
males experience heart failure more frequently 
than females (15 vs. 12/1000 persons per year).31 
This is caused by sex related life style. Alcohol 
consumption, smoking, and lack of motivation 
to seek for care are found more in males than 
females.32
This study is limited to adults aging 18-
75 years old because heart failure in pediatric 
patients has different causes. Most of the study 
subjects in this study were 51-60 years old 
(12 subjects). There were two subjects who 
were less than 40 years old, three between 
40-50 years old, and six who were more than 
60 years old. The median for age in NYHA III 
group was 52 years and the mean in NYHA IV 
group was 58 years. There was no significant 
difference between the age of both groups 
(p=0.076). NYHA IV group had relatively older 
subjects. The Framingham heart study reported 
that heart failure incidence increased with age, 
specifically from 20 to >80 years old.33 In the 
MONICA (Multinational Monitoring Trends 
and Determinants in Cardiovascular Disease) 
Augsburg study, there were 1274 subjects, 2.8% 
were 25-35 years old, and 15.8% were above 65 
years old.31 The Hillington study reported a heart 
failure incidence of 0.2/1000 persons per year 
in the age of 45-55 years and 12.4/1000 persons 
per year in the age of >85 years.31 Heart failure 
in older age is caused by aging where there 
are increasing tissue rigidity, decreasing tissue 
elasticity, increasing fibrosis, and calcification, 
generating intimal thickness, vascular rigidity, 
hypertension, left ventricular hypertrophy, 
arrhythmia, and the heart’s losing ability to 
increase cardiac output as a response to stress.33,34
In this study, the causative factors were CAD 
(56.6%), hypertension (26.1%), DM (8.7%), AF 
(4.3%), and VHD (4.3%). In another perspective, 
CAD was 56.6% and non CAD was 43.4%. In a 
study conducted by Khan, the causative factors 
of heart failure were CAD (35%), hypertension 
(27%), and rheumatic heart disease (13%).27 
Lee reported that in his study, the causing 
factors were CAD (52%), hypertension (26%), 
Sex, age, and causes of heart failure were not 
included. The odd ratio (OR) value (Exp ß) 
of 0.286 and p=0.153. Length of hospital stay 
did not have a significant effect to ST2 levels 
difference.
The curve in Figure 3 shows a weak positive 
correlation between length of hospital stay and 














Figure 3. A curve depicting correlation between length of 
hospital stay and ST2 level difference
DISCUSSION
Within-run precision test for ST2 assay 
yielded a CV of 3.63%, suggesting an acceptable 
analytical performance. The manufacturer’s 
CV is 3.4% for normal control and 2.7% for 
the abnormal. Within-run CV in this study does 
not differ much from the manufacturer’s, and 
fulfill the manufacturer’s regulation which was 
<6.5%.29 As a comparison, Maisel acquired a 
CV of 5.4% and Khan obtained 6.5% in their 
respective studies.27
The study accuracy test also gave a good 
result because ST2 levels that was acquired 
for normal control was still in manufacturer’s 
required range. The sample testing was done in 
one day.
There were 23 study subjects, comprised of 
16 subjects (69.6%) in NYHA III group and 7 
subjects (30.4%) in NYHA IV group. Out of all 
study subjects, there were more males (56.5%) 
than females (43.5%). This finding is similar to 
a study conducted by Djuliana in Jakarta in 40 
heart failure and chronic kidney disease patients 
which had 70% males and 30% females.28 The 
Framingham off spring study in 2012 obtained 
55% females and 45% males out of its 3450 
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and rheumatic heart disease (8%).35 In a study 
conducted by Klatsky to 2594 subjects, 60% of 
heart failures were caused by CAD, and 40% 
by non CAD causes.36 Miller found that CAD 
caused more heart failures (68%) compared to 
non CAD (32%).22 This is also the case with 
Frazier’s study (59% of cases were caused 
by CAD).37 According to American College 
of Cardiologist/American Heart Association, 
persons with high risk of developing heart failure 
are patients with hypertension, CAD, rheumatic 
fever, cardiomyopathy, and DM.2 In this study, 
we also found VHD and AF as causes of heart 
failure in two subjects aging less than 40 years 
old.
CAD and hypertension are caused by 
atherosclerosis, which is the most frequent 
cause of heart failure. Hypertension increases 
progression of CAD and triggers acute myocardial 
infarct by altering blood flow velocity in the 
vasculars.2,32,37,38
Median of ST2 levels at the start of treatment 
in NYHA III group was 30.75 (14.4-84.5 ng/
mL), while the mean in NYHA IV group was 
58.82±37.36 ng/mL. There was no significant 
difference between ST2 levels at the start of 
treatment in NYHA III and NYHA IV group (p 
= 0.89). This was probably caused by the small 
sample size. The higher ST2 levels in NYHA 
IV group compared to NYHA III group shows 
that ST2 levels increase corresponds with heart 
structure damage severity. A study by Rehman 
Januzzi in 2008 found that ST2 levels in patients 
with class IV heart failure was higher than in 
patients with class III and II heart failures.20
In this study, the ST2 levels in NYHA III 
and IV groups at the start of treatment was 
significantly higher than the end (31.4 [14-129.2] 
ng/mL vs. 18.4 [7.6-77.8] ng/mL, p=0.001). 
This result shows that ST2 levels decreases 
significantly as the patient experiences clinical 
improvement. This is in line with what Bhardwaj 
concluded in 2010, that ST2 levels was not just 
an indicator of heart muscle damage, but it also 
changed as the body improves with treatment. 
The better the heart gets, the lesser the ST2 
levels.26
Bivariate and logistic regression analysis 
showed that age, sex, causes of heart failure, and 
length of hospital stay had no effect to ST2 levels 
difference. Even though length of hospital stay 
yielded an OR of 0.286 but it was statistically 
insignificant. This is in accordance with a study 
from Weinberg that reported that race, age, and 
factors causing heart failure had no effect to 
ST2 levels.
CONCLUSION
This study found that ST2 levels could be 
used as a marker of clinical improvement as 
indicated by a significant decrease between pre 
and post treatment.
The change of ST2 levels between the start 
and end of treatment is not affected by age, sex, 
causes of heart failure, and length of hospital 
stay.
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